PharmCADD Co., Ltd.

Based in South Korea, PharmCADD specializes in advanced drug discovery solutions, utilizing innovative technologies to enhance research capabilities in biopharmaceuticals, particularly in mRNA vaccine development and kinase inhibition mechanisms. Founded in 2019 and headquartered in Busan, South Korea, PharmCADD offers advanced drug discovery services. The CEO, Sang-wook Woo, leads a team that has successfully engaged in 5 total deals, with the most recent funding round occurring on April 19, 2021. During this Series B round, PharmCADD raised USD 16.

000 mn, with investments from DSC Investment, KB Securities, KDB Capital, SD Group, and Woori Venture Partners, bringing their total amount raised to USD 16. 000 mn. PharmCADD specializes in advanced drug discovery solutions that leverage technologies such as quantum mechanics, molecular dynamics simulations, and artificial intelligence. The company’s core offerings include the PharmVAC™ platform, focused on mRNA vaccine development, and services that enhance research capabilities in drug design and optimization.

Their solutions address complex biopharmaceutical challenges, particularly related to key kinases like MEK1/2, relevant in various diseases including cancer. In 2022, PharmCADD reported a revenue of USD 481,715. 80, with an EBITDA of USD -6,169,707. 40.

The company generates revenue through partnerships and collaborative agreements with pharmaceutical companies, providing access to their drug discovery platforms and services, which often involve B2B collaborations with milestone payments, licensing fees, and revenue-sharing agreements. Following the Series B funding of USD 16. 000 mn in April 2021, PharmCADD plans to utilize this capital to establish branches in the U. S.

and India, as well as to further their product research and development initiatives. The company is focused on expanding its offerings and market reach, with an emphasis on enhancing their presence within the North American and Indian markets.